Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
December 6, 2004
- FJPWA SEMINAR
December 6, 2004
- Biofermin: Sales Up 1.1% to \3,565 Mil.
December 6, 2004
- BULLETIN
December 6, 2004
- BUSINESS NEWS IN BRIEF
December 6, 2004
- Nissan Chemical: Pharma Sales, Profits Down Sharply
December 6, 2004
- OTC NEWS IN BRIEF
December 6, 2004
- Semi-annual Business Results
December 6, 2004
- Annual Business Results
December 6, 2004
- MEDICAL DEVICE NEWS IN BRIEF
December 6, 2004
- Sales of 26 Leading JPMA Firms Up 0.5%
December 6, 2004
- Semi-annual Business Results
December 6, 2004
- Semi-annual Business Results
December 6, 2004
- Top 28 Post 0.1% Decline in Non-consolidated Sales
December 6, 2004
- VITAL-NET: Profits Down Sharply Despite Growth in Sales
December 6, 2004
- Japan Should Boost Healthcare Spending to 9% of GDP: Mr Butler of PhRMA
December 6, 2004
- SSP: Sales of Rx Drugs Up 6.1% to \5.8 Bil.
December 6, 2004
- NEW PRODUCTS
December 6, 2004
- SSP to Concentrate on Consumer Healthcare: VP Yamashita
December 6, 2004
- Wyeth's Enbrel Receives Import Approval
December 6, 2004
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…